Compare SANM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANM | MDGL |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 12.8B |
| IPO Year | 1994 | 2005 |
| Metric | SANM | MDGL |
|---|---|---|
| Price | $218.55 | $508.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $155.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 479.0K | 187.6K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.07 | N/A |
| EPS | ★ 4.71 | N/A |
| Revenue | ★ $7,890,475,000.00 | $180,133,000.00 |
| Revenue This Year | $74.61 | $58.39 |
| Revenue Next Year | $13.43 | $48.55 |
| P/E Ratio | $46.91 | ★ N/A |
| Revenue Growth | ★ 16.78 | N/A |
| 52 Week Low | $113.71 | $393.61 |
| 52 Week High | $288.68 | $615.00 |
| Indicator | SANM | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 41.57 |
| Support Level | $213.47 | $501.27 |
| Resistance Level | $230.56 | $546.29 |
| Average True Range (ATR) | 9.85 | 16.42 |
| MACD | 2.52 | -2.55 |
| Stochastic Oscillator | 73.07 | 18.73 |
Sanmina Corp is a provider of integrated manufacturing solutions, components, and after-market services to original equipment manufacturers in the communications networks, storage, industrial, defense, and aerospace end markets. The operations are managed as two businesses: Integrated Manufacturing Solutions, which consists of printed circuit board assembly and represents a majority of the firm's revenue; and Components, Products, and Services, which includes interconnect systems and mechanical systems. The firm generates revenue mainly in the United States, China, and Mexico, but has a presence around the world.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.